{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:31:15Z","timestamp":1770485475262,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00277-015-2316-0","type":"journal-article","created":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T11:33:30Z","timestamp":1427369610000},"page":"209-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death"],"prefix":"10.1007","volume":"94","author":[{"given":"Markus","family":"Pfirrmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lauseker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena S.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"issue":"6","key":"2316_CR1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim D-W, Larson RA, Lipton JH, Mahon F-X, Martinelli G, Mayer J, M\u00fcller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sau\u00dfele S, Schiffer C, Silver R, Simonsson B, Steegmann J-L, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884. doi: 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"issue":"9","key":"2316_CR2","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2005.01.112","volume":"23","author":"DJ Sargent","year":"2005","unstructured":"Sargent DJ, Conley BA, Allegra C, Collette L (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23(9):2020\u20132027. doi: 10.1200\/JCO.2005.01.112","journal-title":"J Clin Oncol"},{"key":"2316_CR3","first-page":"423","volume-title":"Cancer clinical trials\u2014methods and practice","author":"DP Byar","year":"1984","unstructured":"Byar DP (1984) Identification of prognostic factors. In: Buyse ME, Staquet MJ, Sylvester RJ (eds) Cancer clinical trials\u2014methods and practice. Oxford University Press, Oxford, pp 423\u2013441"},{"issue":"11","key":"2316_CR4","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850\u2013858","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"2316_CR5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251\u20132259. doi: 10.1056\/NEJMoa0912614","journal-title":"N Engl J Med"},{"issue":"24","key":"2316_CR6","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24):2260\u20132270. doi: 10.1056\/NEJMoa1002315","journal-title":"N Engl J Med"},{"issue":"4","key":"2316_CR7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C, and the Italian Cooperative CML Study Group (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63(4):789\u2013799","journal-title":"Blood"},{"issue":"3","key":"2316_CR8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686\u2013692. doi: 10.1182\/blood-2010-12-319038","journal-title":"Blood"},{"key":"2316_CR9","first-page":"205","volume-title":"Chronic myeloid leukemia\u2014biology and treatment","author":"J Hasford","year":"2001","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Shepherd P, Guilhot F, Mahon FX, Thaler J, Steegmann JL, Kluin-Nelemans HC, Louwagie A, Ohnishi K, Kloke O (2001) Prognostic factors. In: Carella AM, Daley G, Eaves C, Goldman J, Hehlmann R (eds) Chronic myeloid leukemia\u2014biology and treatment. Martin Dunitz, London, pp 205\u2013223"},{"issue":"22","key":"2316_CR10","first-page":"1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ (2009) International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Ann Meet Abstracts 114(22):1126","journal-title":"ASH Ann Meet Abstracts"},{"issue":"5","key":"2316_CR11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saussele S, Hochhaus A (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32(5):415\u2013423. doi: 10.1200\/JCO.2013.49.9020","journal-title":"J Clin Oncol"},{"issue":"10","key":"2316_CR12","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/leu.2013.171","volume":"27","author":"VS Hoffmann","year":"2013","unstructured":"Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, Hellmann A, Prejzner W, Steegmann JL, Mayer J, Indrak K, Colita A, Rosti G, Pfirrmann M (2013) The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 27(10):2016\u20132022. doi: 10.1038\/leu.2013.171","journal-title":"Leukemia"},{"issue":"21","key":"2316_CR13","first-page":"1681","volume":"120","author":"KB Pagnano","year":"2012","unstructured":"Pagnano KB, Lorand-Metze I, Miranda ECM, Duarte VO, Delamain MT, Duarte GO, De Souza CA (2012) EUTOS score is predictive of event-free survival, but not for progression-free and overall survival in patients with early chronic phase chronic myeloid leukemia treated with imatinib: a single institution experience. ASH Annu Meet Abstr 120(21):1681","journal-title":"ASH Annu Meet Abstr"},{"issue":"2","key":"2316_CR14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12185-014-1600-4","volume":"100","author":"SA Yahng","year":"2014","unstructured":"Yahng SA, Jang EJ, Choi SY, Lee SE, Kim SH, Kim DW (2014) Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population. Int J Hematol 100(2):132\u2013140. doi: 10.1007\/s12185-014-1600-4","journal-title":"Int J Hematol"},{"issue":"5","key":"2316_CR15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1179\/1607845412Y.0000000071","volume":"18","author":"B Uz","year":"2013","unstructured":"Uz B, Buyukasik Y, Atay H, Kelkitli E, Turgut M, Bektas O, Eliacik E, Isik A, Aksu S, Goker H, Sayinalp N, Ozcebe OI, Haznedaroglu IC (2013) EUTOS CML prognostic scoring system predicts ELN-based \u2018event-free survival\u2019 better than Euro\/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology 18(5):247\u2013252. doi: 10.1179\/1607845412Y.0000000071","journal-title":"Hematology"},{"key":"2316_CR16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Amer Statis Assn 53:457\u2013481","journal-title":"J Amer Statis Assn"},{"key":"2316_CR17","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the Cox model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York"},{"key":"2316_CR18","unstructured":"Human Mortality Database. Available at www.mortality.org or www.humanmortality.de University of California, Berkeley (USA), and Max Planck Institute of Demographic Research (Germany)"},{"issue":"1","key":"2316_CR19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1541-0420.2011.01640.x","volume":"68","author":"MP Perme","year":"2012","unstructured":"Perme MP, Stare J, Est\u00e8ve J (2012) On estimation in relative survival. Biometrics 68(1):113\u2013120. doi: 10.1111\/j.1541-0420.2011.01640.x","journal-title":"Biometrics"},{"issue":"3","key":"2316_CR20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cmpb.2006.01.004","volume":"81","author":"M Pohar","year":"2006","unstructured":"Pohar M, Stare J (2006) Relative survival analysis in R. Comput Methods Prog Biomed 81(3):272\u2013278. doi: 10.1016\/j.cmpb.2006.01.004","journal-title":"Comput Methods Prog Biomed"},{"issue":"12","key":"2316_CR21","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.compbiomed.2007.04.010","volume":"37","author":"M Pohar","year":"2007","unstructured":"Pohar M, Stare J (2007) Making relative survival analysis relatively easy. Comput Biol Med 37(12):1741\u20131749. doi: 10.1016\/j.compbiomed.2007.04.010","journal-title":"Comput Biol Med"},{"key":"2316_CR22","volume-title":"The statistical analysis of failure time data","author":"JD Kalbfleisch","year":"1980","unstructured":"Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York"},{"issue":"6","key":"2316_CR23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695\u2013706","journal-title":"Stat Med"},{"key":"2316_CR24","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/sim.1070","volume":"21","author":"JB Choudhury","year":"2002","unstructured":"Choudhury JB (2002) Non-Parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 21:1129\u20131144","journal-title":"Stat Med"},{"issue":"3","key":"2316_CR25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16(3):1141\u20131154","journal-title":"Ann Stat"},{"issue":"3","key":"2316_CR26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/ije\/dyr213","volume":"41","author":"PK Andersen","year":"2012","unstructured":"Andersen PK, Geskus RB, de Witte T, Putter H (2012) Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 41(3):861\u2013870. doi: 10.1093\/ije\/dyr213","journal-title":"Int J Epidemiol"},{"issue":"6","key":"2316_CR27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jclinepi.2012.09.017","volume":"66","author":"A Latouche","year":"2013","unstructured":"Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP (2013) A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol 66(6):648\u2013653. doi: 10.1016\/j.jclinepi.2012.09.017","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2316_CR28","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26(11):2389\u20132430","journal-title":"Stat Med"},{"issue":"446","key":"2316_CR29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"2316_CR30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-11-86","volume":"11","author":"A Allignol","year":"2011","unstructured":"Allignol A, Schumacher M, Wanner C, Drechsler C, Beyersmann J (2011) Understanding competing risks: a simulation point of view. BMC Med Res Methodol 11:86. doi: 10.1186\/1471-2288-11-86","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"2316_CR31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381\u2013387. doi: 10.1038\/sj.bmt.1705727","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2316_CR32","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/bmt.2009.359","volume":"45","author":"L Scrucca","year":"2010","unstructured":"Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45(9):1388\u20131395","journal-title":"Bone Marrow Transplant"},{"issue":"7019","key":"2316_CR33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/bmj.311.7019.1539","volume":"311","author":"JC Wyatt","year":"1995","unstructured":"Wyatt JC, Altman DG (1995) Commentary: prognostic models: clinically useful or quickly forgotten? BMJ 311(7019):1539\u20131541. doi: 10.1136\/bmj.311.7019.1539","journal-title":"BMJ"},{"issue":"9","key":"2316_CR34","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Gohring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hanel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saussele S, Hochhaus A (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26(9):2096\u20132102. doi: 10.1038\/leu.2012.85","journal-title":"Leukemia"},{"issue":"9","key":"2316_CR35","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/leu.2011.116","volume":"25","author":"M Pfirrmann","year":"2011","unstructured":"Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J (2011) Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 25(9):1433\u20131438","journal-title":"Leukemia"},{"issue":"1","key":"2316_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-2141.2001.02873.x","volume":"114","author":"M Pfirrmann","year":"2001","unstructured":"Pfirrmann M, Hasford J (2001) Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon: comments. Br J Haematol 114(1):241\u2013243","journal-title":"Br J Haematol"},{"issue":"suppl 5","key":"2316_CR37","first-page":"302","volume":"37","author":"M Pfirrmann","year":"2014","unstructured":"Pfirrmann M, Saussele S, Baccarani M, Guilhot J, Cervantes F, Ossenkoppele G, Lindoerfer D, Hoffmann VS, Castagnetti F, Hehlmann R, Simonsson B (2014) Overall survival and prognosis in 2190 patients with first-line imatinib treatment considering the event \u201cdeath due to chronic myeloid leukemia\u201d. Oncol Res Treat 37(suppl 5):302","journal-title":"Oncol Res Treat"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2316-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2316-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T05:23:48Z","timestamp":1598851428000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2316-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":37,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2316"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2316-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}